Brean Capital Analysts Give Vanda Pharmaceuticals Inc. (VNDA) a $24.00 Price Target
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) received a $24.00 price objective from equities research analysts at Brean Capital in a research note issued to investors on Monday. The brokerage presently has a a “buy” rating on the biopharmaceutical company’s stock. Brean Capital’s target price suggests a potential upside of 36.13% from the stock’s current price.
Other equities research analysts have also recently issued research reports about the stock. Piper Jaffray Cos. set a $16.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 18th. Jefferies Group assumed coverage on shares of Vanda Pharmaceuticals in a report on Thursday, October 6th. They issued a “buy” rating and a $23.00 price target on the stock. JMP Securities lifted their price target on shares of Vanda Pharmaceuticals from $18.00 to $22.00 and gave the stock a “market outperform” rating in a report on Friday, August 26th. Finally, Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $20.00.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 2.10% during midday trading on Monday, hitting $17.26. The company’s stock had a trading volume of 543,930 shares. The firm’s market cap is $747.08 million. Vanda Pharmaceuticals has a 52-week low of $6.91 and a 52-week high of $18.00. The stock’s 50 day moving average is $15.70 and its 200-day moving average is $11.69.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/brean-capital-analysts-give-vanda-pharmaceuticals-inc-vnda-a-24-00-price-target.html
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.12. Vanda Pharmaceuticals had a negative return on equity of 22.51% and a negative net margin of 31.85%. The firm had revenue of $36.02 million for the quarter, compared to the consensus estimate of $36.03 million. During the same quarter in the previous year, the business earned ($0.13) EPS. The company’s revenue was up 30.6% compared to the same quarter last year. Equities analysts predict that Vanda Pharmaceuticals will post ($0.61) EPS for the current fiscal year.
In other Vanda Pharmaceuticals news, insider James E. Flynn sold 547,886 shares of the business’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $15.66, for a total transaction of $8,579,894.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider James E. Flynn sold 1,120,461 shares of the business’s stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $16.56, for a total transaction of $18,554,834.16. The disclosure for this sale can be found here. Company insiders own 8.45% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Sphera Funds Management LTD. boosted its position in Vanda Pharmaceuticals by 10.8% in the first quarter. Sphera Funds Management LTD. now owns 512,051 shares of the biopharmaceutical company’s stock valued at $4,281,000 after buying an additional 50,000 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in Vanda Pharmaceuticals by 0.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 89,624 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 780 shares during the last quarter. Boston Advisors LLC boosted its position in Vanda Pharmaceuticals by 0.7% in the second quarter. Boston Advisors LLC now owns 36,190 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 245 shares during the last quarter. Princeton Alpha Management LP purchased a new position in Vanda Pharmaceuticals during the second quarter valued at $218,000. Finally, Acrospire Investment Management LLC purchased a new position in Vanda Pharmaceuticals during the first quarter valued at $102,000. 86.06% of the stock is currently owned by institutional investors and hedge funds.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.